{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T21:29:50Z","timestamp":1772141390198,"version":"3.50.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Academy of Finland, Jane and Aatos Erkko Foundation"},{"name":"Sigrid Juselius Foundation"},{"DOI":"10.13039\/501100005633","name":"Finnish Foundation for Cardiovascular Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007797","name":"University of Helsinki","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007797","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Helsinki University Hospital"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Cytomegalovirus (CMV) predisposes lung transplant (LTx) recipients to acute rejections and chronic lung allograft dysfunction (CLAD). Guidelines recommend standard-dose valganciclovir (VGCV, 900 mg daily) prophylaxis, while evidence for low-dose VGCV (450 mg daily) in CMV seropositive recipients remains limited. We evaluated the efficacy and safety of low-dose VGCV prophylaxis in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analysed 137 adult CMV seropositive primary LTx recipients receiving triple-drug immunosuppression without induction therapy. Recipients received low-dose VGCV (450 mg daily for \u22656 months), or standard-standard dose (900 mg daily for \u22656 months), if &amp;gt; 80% of the prophylaxis period was completed at the respective dose. Routine CMV monitoring was performed during prophylaxis and 3 months after discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 120 eligible seropositive LTx recipients, 97 (80.8%) received low-dose and 23 (19.2%) received standard-dose VGCV with median durations of 272 and 246 days, respectively. Seventeen recipients (12%) with mixed dosing were excluded. One patient in each group discontinued prophylaxis due to severe leucopenia. Breakthrough CMV-DNAemia occurred in 3.1% of low-dose patients. Post-prophylaxis CMV episodes were common but occurred independently of VGCV dose or duration. No VGCV resistance was detected. Leucopenia was frequent and similarly unrelated to dose or duration. Rates of acute rejections (P\u2009=\u2009.358) or overall survival (P\u2009=\u2009.889) were similar, while low-dose VGCV prophylaxis was associated with improved CLAD-free survival (HR 2.30, 95% CI 1.33-3.97, P\u2009=\u2009.003).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In CMV-seropositive adult LTx recipients without induction therapy, low-dose VGCV prophylaxis was as safe and effective as standard-dose prophylaxis and was associated with superior CLAD-free survival. Future randomized clinical trial is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejcts\/ezag095","type":"journal-article","created":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T12:35:26Z","timestamp":1771158926000},"source":"Crossref","is-referenced-by-count":0,"title":["Safety and Effectiveness of Low-Dose Valganciclovir Prophylaxis in Cytomegalovirus Seropositive Lung Transplant Recipients"],"prefix":"10.1093","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-4192-5124","authenticated-orcid":false,"given":"Rasmus A J","family":"Lehikoinen","sequence":"first","affiliation":[{"name":"Transplantation Laboratory, University of Helsinki , Helsinki, 00014,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antti","family":"Nyk\u00e4nen","sequence":"additional","affiliation":[{"name":"Transplantation Laboratory, University of Helsinki , Helsinki, 00014,","place":["Finland"]},{"name":"Department of Cardiothoracic Surgery, Helsinki University Hospital , Helsinki, 00029,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simo O","family":"Syrj\u00e4l\u00e4","sequence":"additional","affiliation":[{"name":"Transplantation Laboratory, University of Helsinki , Helsinki, 00014,","place":["Finland"]},{"name":"Department of Cardiothoracic Surgery, Helsinki University Hospital , Helsinki, 00029,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kishor U","family":"Dhaygude","sequence":"additional","affiliation":[{"name":"Transplantation Laboratory, University of Helsinki , Helsinki, 00014,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Ristikankare","sequence":"additional","affiliation":[{"name":"Transplantation Laboratory, University of Helsinki , Helsinki, 00014,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elina","family":"Heli\u00f6vaara","sequence":"additional","affiliation":[{"name":"Deparment of Pulmonology, Helsinki University Hospital , Helsinki, 00029,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9517-318X","authenticated-orcid":false,"given":"Jussi","family":"Tikkanen","sequence":"additional","affiliation":[{"name":"Deparment of Pulmonology, Helsinki University Hospital , Helsinki, 00029,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl B","family":"Lemstr\u00f6m","sequence":"additional","affiliation":[{"name":"Transplantation Laboratory, University of Helsinki , Helsinki, 00014,","place":["Finland"]},{"name":"Department of Cardiothoracic Surgery, Helsinki University Hospital , Helsinki, 00029,","place":["Finland"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"2026022615511665500_ezag095-B1","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1600-6143.2011.03837.x","article-title":"Is prevention the best treatment? CMV after lung transplantation","volume":"12","author":"Patel","year":"2012","journal-title":"Am J Transplant"},{"key":"2026022615511665500_ezag095-B2","doi-asserted-by":"publisher","first-page":"1753466619878555","DOI":"10.1177\/1753466619878555","article-title":"Tailored combined cytomegalovirus management in lung transplantation: a retrospective analysis","volume":"13","author":"Solidoro","year":"2019","journal-title":"Ther Adv Respir Dis"},{"key":"2026022615511665500_ezag095-B3","doi-asserted-by":"publisher","first-page":"e12893","DOI":"10.1111\/tid.12893","article-title":"Clinical significance of post-prophylaxis cytomegalovirus infection in lung transplant recipients","volume":"20","author":"Jaamei","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"2026022615511665500_ezag095-B4","doi-asserted-by":"publisher","first-page":"e13069","DOI":"10.1111\/tid.13069","article-title":"Cytomegalovirus viremia in lung transplantation during and after prophylaxis","volume":"21","author":"Chang","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"2026022615511665500_ezag095-B5","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"2026022615511665500_ezag095-B6","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/MOT.0000000000000753","article-title":"Survival in adult lung transplantation: where are we in 2020?","volume":"25","author":"Bos","year":"2020","journal-title":"Curr Opin Organ Transplant"},{"key":"2026022615511665500_ezag095-B7","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.healun.2019.08.001","article-title":"The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult lung and heart-lung transplantation report-2019; focus theme: donor and recipient size match","volume":"38","author":"Chambers","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"2026022615511665500_ezag095-B8","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1164\/rccm.200911-1786OC","article-title":"Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation","volume":"181","author":"Snyder","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"2026022615511665500_ezag095-B9","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1111\/j.1600-6143.2011.03663.x","article-title":"Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome","volume":"11","author":"Paraskeva","year":"2011","journal-title":"Am J Transplant"},{"key":"2026022615511665500_ezag095-B10","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.healun.2007.10.017","article-title":"Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection","volume":"26","author":"Stewart","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"2026022615511665500_ezag095-B11","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.healun.2019.03.009","article-title":"Chronic lung allograft dysfunction: definition, diagnostic criteria, and approaches to treatment-a consensus report from the pulmonary council of the ISHLT","volume":"38","author":"Verleden","year":"2019","journal-title":"J Heart Lung Transplant"},{"key":"2026022615511665500_ezag095-B12","doi-asserted-by":"publisher","first-page":"e13512","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in solid organ transplant recipients-guidelines of the American Society of Transplantation infectious diseases community of practice","volume":"33","author":"Razonable","year":"2019","journal-title":"Clin Transplant"},{"key":"2026022615511665500_ezag095-B13","doi-asserted-by":"publisher","first-page":"CD003774","DOI":"10.1002\/14651858.CD003774.pub5","article-title":"Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients","volume":"5","author":"Vernooij","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"2026022615511665500_ezag095-B14","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1111\/tid.12609","article-title":"Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+\/R+) renal transplant recipients","volume":"18","author":"Heldenbrand","year":"2016","journal-title":"Transpl Infect Dis"},{"key":"2026022615511665500_ezag095-B15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/tid.12349","article-title":"Increased risk of breakthrough infection among cytomegalovirus donor-positive\/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis","volume":"17","author":"Stevens","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"2026022615511665500_ezag095-B16","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/j.1399-0012.2007.00761.x","article-title":"Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes","volume":"22","author":"Eid","year":"2008","journal-title":"Clin Transplant"},{"key":"2026022615511665500_ezag095-B17","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1177\/15269248211046037","article-title":"Low-Dose valganciclovir prophylaxis is safe and cost-saving in CMV-seropositive kidney transplant recipients","volume":"31","author":"Shi","year":"2021","journal-title":"Prog Transplant"},{"key":"2026022615511665500_ezag095-B18","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/lt.25047","article-title":"Low-dose valganciclovir for cytomegalovirus prophylaxis in intermediate-risk liver transplantation recipients","volume":"24","author":"Khan","year":"2018","journal-title":"Liver Transpl"},{"key":"2026022615511665500_ezag095-B19","doi-asserted-by":"publisher","first-page":"e12868","DOI":"10.1111\/tid.12868","article-title":"Low-dose valganciclovir prohylaxis is efficacious and safe in cytomegalovirus seropositive heart transplant recipients with anti-thymocyte globulin","volume":"20","author":"Eriksson","year":"2018","journal-title":"Transpl Infect Dis"},{"key":"2026022615511665500_ezag095-B20","doi-asserted-by":"publisher","first-page":"101268","DOI":"10.1016\/j.lanepe.2025.101268","article-title":"Safety and efficacy of immunoguided prophylaxis for cytomegalovirus disease in low-risk lung transplant recipients in Spain: a multicentre, open-label, randomised, phase 3, noninferiority trial","volume":"52","author":"P\u00e1ez-Vega","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"2026022615511665500_ezag095-B21","doi-asserted-by":"publisher","first-page":"706","DOI":"10.4081\/mrm.2021.706","article-title":"Efficacy of low-dose valganciclovir in CMV R+ lung transplant recipients: a retrospective comparative analysis","volume":"16","author":"Hunt","year":"2021","journal-title":"Multidiscip Respir Med"},{"key":"2026022615511665500_ezag095-B22","doi-asserted-by":"publisher","first-page":"e2023","DOI":"10.1002\/rmv.2023","article-title":"Systematic review of ganciclovir pharmacodynamics during the prevention of cytomegalovirus infection in adult solid organ transplant recipients","volume":"29","author":"Wong","year":"2019","journal-title":"Rev Med Virol"}],"container-title":["European Journal of Cardio-Thoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejcts\/advance-article-pdf\/doi\/10.1093\/ejcts\/ezag095\/66960336\/ezag095.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejcts\/article-pdf\/68\/2\/ezag095\/66960336\/ezag095.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejcts\/article-pdf\/68\/2\/ezag095\/66960336\/ezag095.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:51:25Z","timestamp":1772139085000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejcts\/article\/doi\/10.1093\/ejcts\/ezag095\/8488732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ejcts\/ezag095","relation":{},"ISSN":["1010-7940","1873-734X"],"issn-type":[{"value":"1010-7940","type":"print"},{"value":"1873-734X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,2]]},"article-number":"ezag095"}}